Henry Gosebruch is now chief executive of the spinout, which has roughly $2.5 billion and plans to use dealmaking to build a ...

The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing ...

The law in particular will affect CVS and UnitedHealth, both of which operate physical pharmacies in the state along with ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” ...

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...